^
Association details:
| Biomarker: | BAP1 581-17_585del22 + RAD21 amplification |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
Published date:
11/27/2020
Excerpt:
We present a 56-year-old male patient affected with metastatic ICC...A novel BAP1 mutation (splice site c.581-17_585del22) and a RAD21 amplification were identified...patient was treated with PARP inhibitor olaparib. The patient had a partial response....with an overall survival of 37.2 months from the time of diagnosis of his ICC. Following 11.0 months on olaparib treatment, sustained stable disease control is ongoing.
DOI:
10.3389/fonc.2020.567289
